Format

Send to

Choose Destination
Cancer Discov. 2018 Apr;8(4):417-427. doi: 10.1158/2159-8290.CD-17-1227. Epub 2018 Feb 5.

Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAFV600E Colorectal Cancer.

Author information

1
Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
2
Department of Medicine, Harvard Medical School, Boston, Massachusetts.
3
Dana-Farber Cancer Institute, Boston, Massachusetts.
4
Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts.
5
Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts.
6
Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
7
Massachusetts General Hospital Cancer Center, Boston, Massachusetts. rbcorcoran@partners.org.

Abstract

Clonal heterogeneity associated with acquired resistance presents a critical therapeutic challenge. Whole-exome sequencing of paired tumor biopsies and targeted sequencing of cell-free DNA (cfDNA) from patients with BRAFV600E colorectal cancer receiving BRAF inhibitor combinations identified 14 distinct alterations in MAPK pathway components driving acquired resistance, with as many as eight alterations in a single patient. We developed a pooled clone system to study clonal outgrowth during acquired resistance, in vitro and in vivoIn vitro, the dynamics of individual resistant clones could be monitored in real time in cfDNA isolated from culture media during therapy. Outgrowth of multiple resistant clones was observed during therapy with BRAF, EGFR, and MEK inhibitor combinations. However, ERK inhibition, particularly in combination with BRAF and EGFR inhibition, markedly abrogated clonal outgrowth in vitro and in vivo Thus, convergent, up-front therapy may suppress outgrowth of heterogeneous clones harboring clinically observed resistance alterations, which may improve clinical outcome.Significance: We observed heterogeneous, recurrent alterations in the MAPK pathway as key drivers of acquired resistance in BRAFV600E colorectal cancer, with multiple concurrent resistance alterations detectable in individual patients. Using a novel pooled clone system, we identify convergent up-front therapeutic strategies capable of intercepting multiple resistance mechanisms as potential approaches to suppress emergence of acquired resistance. Cancer Discov; 8(4); 417-27. ©2018 AACR.See related commentary by Janku, p. 389See related article by Corcoran et al., p. 428This article is highlighted in the In This Issue feature, p. 371.

PMID:
29431697
PMCID:
PMC5882515
[Available on 2019-04-01]
DOI:
10.1158/2159-8290.CD-17-1227

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center